Dr David Collingridge is a Visiting Professor of Global Oncology in the School of Cancer & Pharmaceutical Sciences at King's.

He is the Editor-in-Chief of The Lancet Oncology and Vice President of editorial strategy and innovation for The Lancet’s large portfolio of clinical journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK.

Dr Collingridge has won awards for projects focused on cancer control in low-to-middle income countries; has published numerous peer-review articles, editorials, opinion pieces, and news reports; has co-authored a textbook on radiobiology and has been a contributor to various other books. He lectures on the publishing industry, how to write a successful manuscript, health activism, and clinical trial design, and was formally a Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA.